In stage 3 CKD, SGLT2 inhibitors reduce the risk of primary cardiovascular outcomes by 26% overall: 30% in stage 3a, 23% in stage 3b, and 29% in stage 4 CKD. Here, SLC5A2 is linked to chronic kidney disease.